Stonebridge Ventures

Stonebridge Ventures

The firm's website highlights a concentrated set of Korean deep-tech portfolio companies, including AI semiconductor developer OpenEdge, defense-drone maker S2W, and Onconic Therapeutics, the developer behind South Korea’s 37th novel drug. These positions suggest a generalist venture mandate that moves from seed through pre-IPO, though the firm does not publicly break out its vehicle structures or fund sizes. Stonebridge Ventures maintains a public commitment to the Stewardship Code, signaling institutional governance alongside its investment activity. The firm’s website, while minimal, is primarily in Korean and focuses on company logos rather than fund or team disclosures — a pattern consistent with a manager that relies on domestic LP relationships and network-driven sourcing rather than outbound institutional marketing. Given the limited public disclosures, several key details remain unconfirmed: the identities of Stonebridge Ventures’ founding partners, the firm’s total assets under management, and its specific geographic reach beyond South Korea. The website’s internal pages — including those for team, strategy, and portfolio — return server errors, indicating the firm has not maintained a complete public-facing web presence as of the last scrape. What distinguishes Stonebridge Ventures structurally is not a disclosed hybrid model or a co-investment club, but its posture as a Korean venture manager operating across both civilian deep-tech and defense applications — pairing AI semiconductor and autonomous drone investments under one roof. This dual-use concentration is unusual even among Seoul-based venture firms and likely shapes a distinct LP base and regulatory interface.